Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
|Articles|September 14, 2021
Updates in the Treatment of Diffuse Large B-Cell Lymphoma
Advertisement
This article discusses the current treatment landscape and therapeutic strategies for relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL), the role of CAR T-cell therapies in R/R DLBCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.
Advertisement
Related to this article
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
Roswell Park Comprehensive Cancer Center recognized members of its clinical, research and healthcare teams during the second annual Excellence Awards.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 9/20
4
Iberdomide Plus Daratumumab/Dexamethasone Improves MRD-Negative CR vs DVd in Relapsed/Refractory Myeloma
5